Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 5, 2011, Pages 498-503

  St Peter, Wendy L ^a,b   Farley, T Michael ^c   Carter, Barry L ^c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

collaborative care; hypertension; management; pharmacist

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG DOSE REGIMEN; GENERAL PRACTITIONER; HEALTH CARE; HEALTH CARE MANAGEMENT; HUMAN; MEDICAL HOME MODEL; MODEL; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHRONIC DISEASE; COMORBIDITY; COOPERATIVE BEHAVIOR; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MEDICATION ADHERENCE; PATIENT CARE TEAM; PHARMACISTS; PHYSICIANS, PRIMARY CARE; TREATMENT OUTCOME;

EID: 80051801008     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834902c8     Document Type: Review

References (35)

1. Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010;55:441-451. This article is important because it adds to the evidence that hypertension control is poor in CKD patients, even when the less stringent definition of control (<140/90 mmHg) is used.
2. Muntner P, Judd SE, Krousel-Wood M, et al. Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2010;56:447-457. There have been multiple studies that have documented poor adherence to medications in CKD patients, but this study expands the available literature by showing that patients who have self-reported nonadherence have higher odds ratios for uncontrolled hypertension. In the general population pharmacists have consistently been shown to improve adherence to antihypertensive medications.
3. Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of hypertension: United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep 2011;60:103-108. This study found slightly lower BP control rates than some other evaluations of national data. The fact that BP control was not at 50%, especially in minority populations, highlights the need for more aggressive strategies to improve BP control.
4. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Available at: http://www.iom.edu/Reports/2009/ Comparative-EffectivenessResearchPriorities.aspx. [Report released 30 June 2009; Web page updated 11 October 2009; Accessed 3 March 2011]
5. Chisholm-Burns MA, Kim LJ, Spivey CA, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care 2010;48:923-933. This is the most comprehensive meta-analysis of studies that involve the various activities performed by pharmacists involved with chronic medication management. It also has extensive evaluations of the different study settings (e.g. inpatient vs. outpatient) and humanistic outcomes such as patient satisfaction and qualityof-life.
6. Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med 2009;169:1748-1755.
7. Carter BL, Ardery G, Dawson JD, et al. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med 2009;169:1996-2002.
8. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood) 2008;27:759-769. (Pubitemid 351770245)
9. U. S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
10. Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA 2008;299:2857-2867. (Pubitemid 351930885)
11. Bunting BA, Smith BH, Sutherland SE. The Asheville project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc 2008;48:23-31.
12. Weber CA, Ernst ME, Sezate GS, et al. Pharmacist-physician comanagement of hypertension and reduction in 24-h ambulatory blood pressures. Arch Intern Med 2010;170:1634-1639. This is the first in-depth evaluation of any team-based care strategy that examined 24-h ambulatory BP monitoring. As 24-h ABPM is becoming the gold standard as an objective method to assess therapeutic drug trials, such evaluations will be increasingly important to assess the overall circadian patterns of BP control following team-based care strategies.
13. Wentzlaff DM, Carter BL, Ardery G, et al. Sustained blood pressure control following discontinuation of a pharmacist intervention. J Clin Hypertens (Greenwich) 2011;13:431-437. There is only one prospective, controlled evaluation of the effect of discontinuing a pharmacist intervention for hypertension and it was published in 1973. The above study was a retrospective evaluation following discontinuation of a 6-month intervention. Future prospective studies must evaluate the sustainability of such interventions once the intervention is stopped.
14. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563-2571. (Pubitemid 44903860)
15. Von Muenster SJ, Carter BL, Weber CA, et al. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci 2008;30:128-135. (Pubitemid 350172660)
16. Rifkin DE, Laws MB, Rao M, et al. Medication adherence behavior and priorities among older adults with CKD: a semistructured interview study. Am J Kidney Dis 2010;56:439-446. This semi-structured interview study in 20 CKD stages 3-5D patients regarding medication adherence behaviors showed that many CKD patients held medication beliefs or priorities that were nonconcordant with medical opinion, but patients rarely discussed these issues with their physicians.
17. Gallagher H, de Lusignan S, Harris K, Cates C. Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review. Br J Gen Pract 2010;60:e258-e265. This systematic review is the first to summarize the effect of quality improvement interventions for hypertension management in CKD patients.
18. Medical Home Initiatives for Children with Special Needs Project Advisory Committee, American Academy of Pediatrics. The medical home. Pediatrics 2002;110:184-186.
19. American Academy of Family Physicians. Joint principles of the patientcentered medical home. Del Med J 2008;80:21-22.
20. Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Aff (Millwood) 2001;20:64-78. (Pubitemid 33707442)
21. Bates DW. Role of pharmacists in the medical home. Am J Health Syst Pharm 2009;66:1116-1118.
22. Willis JS, Hoy RH, Jenkins WD. In-home medication reviews: a novel approach to improving patient care through coordination of care. J Community Health 2011-April 17 [Epub ahead of print]. This study evaluated a new model for medication reviews within the context of the medical home. Evaluation of benefits and difficulties are discussed.
23. Smith M, Bates DW, Bodenheimer T, Cleary PD. Why pharmacists belong in the medical home. Health Aff (Millwood) 2010;29:906-913. This study evaluated the role of a pharmacist as part of medical home via reviewing demonstration projects that have been published in the liturature.
24. Kozminski M, Busby R, McGivney MS, et al. Pharmacist integration into the medical home: qualitative analysis. J Am Pharm Assoc 2011;51:173-183. This study captures attitudes, identified by participants by members of the medical home towards inclusion of a pharmacist. These results provide guidance to clinicians and insight into strategies for building a pharmacist-integrated medical home team.
25. Nkansah N, Mostovetsky O, Yu C, et al. Effect of outpatient pharmacists' nondispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev 2010; July 7:CD000336.
26. St Peter WL. Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation. Adv Chronic Kidney Dis 2010;17:413-419.
27. Tam VC, Knowles SR, Cornish PL, et al. Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review. CMAJ 2005;173:510-515. (Pubitemid 41225048)
28. Meran S, Don K, Shah N, et al. Impact of chronic kidney disease management in primary care. QJM 2011;104:27-34.
29. Stevens PE, Farmer CK, Hallan SI. The primary care physician: nephrology interface for the identification and treatment of chronic kidney disease. J Nephrol 2010;23:23-32.
30. Borsellino M. CCSA 09: renal program allows pharmacy team to shine. Available at: http://www.canadianhealthcarenetwork.ca/pharmacists/events/awards/ ccsa-09-renal-program-allows-pharmacy-team-to-shine-2284 [accessed 5 October 2011].
31. Allen AS, Forman JP, Orav EJ, et al. Primary care management of chronic kidney disease. J Gen Intern Med 2011;26:386-392. A large proportion of CKD patients are seen within primary care settings. This retrospective study was important in that they found significant deficiencies in quality of CKD care, (including achievement of BP targets), within 1 5 primary care settings in one state. This study highlights the necessity to test new care models to improve hypertension management in CKD patients within primary care practices.
32. National Committee for Quality Assurance. Patient-centered medical home. Available at: http://www.ncqa.org/tabid/631/Default.aspx [accessed 5 April 2011].
33. Sica DA. Pharmacologic issues in treating hypertension in CKD. Adv Chronic Kidney Dis 2011;18:42-47.
34. Mason NA, Bakus JL. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin Dial 2010;23:55-61. This evaluatation is a multifaceted process for comprehensive medication history interview, structured therapy assessment, and open communication between members of the medical team to improve phamacuetical care in patients with CKD.
35. Leal S, Soto M. Chronic kidney disease risk reduction in a Hispanic population through pharmacist-based disease-state management. Adv Chronic Kidney Dis 2008;15:162-167. (Pubitemid 351335416)